Nowadays, differentiation syndrome is a common occurrence during treatment with small-molecule inhibitors that target mutations commonly found in AML, such as FLT3 inhibitors, IDH inhibitors, and menin inhibitors [43]. The gene discussed is FLT3; the disease is acute myeloid leukemia.